166 related articles for article (PubMed ID: 38166898)
21. HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes.
Li J; Yao J; Qi L
Sci Rep; 2023 Dec; 13(1):21753. PubMed ID: 38066224
[TBL] [Abstract][Full Text] [Related]
22. Identification of disulfidptosis-related genes and subgroups in Alzheimer's disease.
Ma S; Wang D; Xie D
Front Aging Neurosci; 2023; 15():1236490. PubMed ID: 37600517
[TBL] [Abstract][Full Text] [Related]
23. Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer.
Jin T; Yin T; Xu R; Liu H; Yuan S; Xue Y; Zhang J; Wang H
Transl Oncol; 2024 Jun; 44():101938. PubMed ID: 38492499
[TBL] [Abstract][Full Text] [Related]
24. Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses.
Liu S; Zheng Y; Li S; Du Y; Liu X; Tang H; Meng X; Zheng Q
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16851-16867. PubMed ID: 37736788
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
26. Construction and validation of a transient receptor potential-related long noncoding RNA signature for prognosis prediction in breast cancer patients.
Guo Q; Qiu P; Pan K; Chen J; Wang B; Lin J
Medicine (Baltimore); 2023 Nov; 102(46):e35978. PubMed ID: 37986367
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
[TBL] [Abstract][Full Text] [Related]
28. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
[TBL] [Abstract][Full Text] [Related]
29. Prognosis stratification of patients with breast invasive carcinoma based on cysteine metabolism-disulfidptosis affinity.
Zhang Y; Ye Y; Xu A; Luo Y; Sun Y; Zhang W; Ji L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11979-11994. PubMed ID: 37422541
[TBL] [Abstract][Full Text] [Related]
30. An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.
Qiu P; Guo Q; Lin J; Pan K; Chen J; Ding M
Sci Rep; 2022 Dec; 12(1):22322. PubMed ID: 36566321
[TBL] [Abstract][Full Text] [Related]
31. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
32. A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing.
Liao Z; Cheng Y; Zhang H; Jin X; Sun H; Wang Y; Yan J
Front Cell Dev Biol; 2023; 11():1308352. PubMed ID: 38033866
[No Abstract] [Full Text] [Related]
33. Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment.
Tang Z; Li L; Huang X; Zhao Y; Liu Q; Zhang C
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38213151
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
36. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
37. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
38. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
39. Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data.
Wang X; Jiang S; Zhou X; Wang X; Li L; Tang J
Oncol Res; 2023; 31(5):697-714. PubMed ID: 37547756
[TBL] [Abstract][Full Text] [Related]
40. Identification of disulfidptosis-related genes and analysis of immune infiltration characteristics in ischemic strokes.
Qin R; Huang L; Xu W; Qin Q; Liang X; Lai X; Huang X; Xie M; Chen L
Math Biosci Eng; 2023 Oct; 20(10):18939-18959. PubMed ID: 38052584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
